Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, 63110, USA.
Department of Molecular and Human Genetics, Baylor College of Medicine (BCM), Houston, TX, 77030, USA.
Orphanet J Rare Dis. 2021 May 7;16(1):206. doi: 10.1186/s13023-021-01839-9.
Decreased sequencing costs have led to an explosion of genetic and genomic data. These data have revealed thousands of candidate human disease variants. Establishing which variants cause phenotypes and diseases, however, has remained challenging. Significant progress has been made, including advances by the National Institutes of Health (NIH)-funded Undiagnosed Diseases Network (UDN). However, 6000-13,000 additional disease genes remain to be identified. The continued discovery of rare diseases and their genetic underpinnings provides benefits to affected patients, of whom there are more than 400 million worldwide, and also advances understanding the mechanisms of more common diseases. Platforms employing model organisms enable discovery of novel gene-disease relationships, help establish variant pathogenicity, and often lead to the exploration of underlying mechanisms of pathophysiology that suggest new therapies. The Model Organism Screening Center (MOSC) of the UDN is a unique resource dedicated to utilizing informatics and functional studies in model organisms, including worm (Caenorhabditis elegans), fly (Drosophila melanogaster), and zebrafish (Danio rerio), to aid in diagnosis. The MOSC has directly contributed to the diagnosis of challenging cases, including multiple patients with complex, multi-organ phenotypes. In addition, the MOSC provides a framework for how basic scientists and clinicians can collaborate to drive diagnoses. Customized experimental plans take into account patient presentations, specific genes and variant(s), and appropriateness of each model organism for analysis. The MOSC also generates bioinformatic and experimental tools and reagents for the wider scientific community. Two elements of the MOSC that have been instrumental in its success are (1) multidisciplinary teams with expertise in variant bioinformatics and in human and model organism genetics, and (2) mechanisms for ongoing communication with clinical teams. Here we provide a position statement regarding the central role of model organisms for continued discovery of disease genes, and we advocate for the continuation and expansion of MOSC-type research entities as a Model Organisms Network (MON) to be funded through grant applications submitted to the NIH, family groups focused on specific rare diseases, other philanthropic organizations, industry partnerships, and other sources of support.
测序成本的降低导致了遗传和基因组数据的爆炸式增长。这些数据揭示了数千个人类疾病候选变体。然而,确定哪些变体导致表型和疾病仍然具有挑战性。包括美国国立卫生研究院(NIH)资助的未确诊疾病网络(UDN)在内的研究已经取得了重大进展。然而,仍有 6000-13000 个额外的疾病基因有待发现。不断发现罕见疾病及其遗传基础,不仅使全球 4 亿多受影响的患者受益,还有助于深入了解更常见疾病的发病机制。利用模式生物的平台可以发现新的基因-疾病关系,帮助确定变异的致病性,并且通常可以深入探索病理生理学的潜在机制,从而提出新的治疗方法。UDN 的模式生物筛选中心(MOSC)是一个独特的资源,致力于利用信息学和模式生物中的功能研究,包括线虫(秀丽隐杆线虫)、果蝇(黑腹果蝇)和斑马鱼(斑马鱼),以辅助诊断。MOSC 直接促成了对具有挑战性病例的诊断,包括多名患有复杂多器官表型的患者。此外,MOSC 为基础科学家和临床医生如何合作推动诊断提供了一个框架。定制的实验计划考虑到患者的表现、特定的基因和变体,以及每个模式生物用于分析的适当性。MOSC 还为更广泛的科学界生成生物信息学和实验工具和试剂。MOSC 成功的两个要素是:(1)具有变体生物信息学和人类及模式生物遗传学专业知识的多学科团队;(2)与临床团队持续沟通的机制。在这里,我们就模式生物在继续发现疾病基因方面的核心作用发表一份立场声明,并主张继续和扩大 MOSC 类型的研究实体作为一个通过向 NIH 提交拨款申请、专注于特定罕见疾病的家族团体、其他慈善组织、行业合作伙伴关系和其他支持来源资助的模式生物网络(MON)。